Other examples include epidermal growth factor receptor (EGFR) immunohistochemistry and KRAS proto-oncogene (KRAS) exon 2 mutation tests for determining the likelihood of treatment response to cetuximab or panitumumab treatment in metastatic colorectal cancer (CRC) [33]. The gene discussed is EGFR; the disease is colorectal carcinoma.